Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728210 | 0.86 | MCL1 (0.52) | MCL1BCL2L1CA1CA2CA12 | |
| SCHEMBL12581048 | 0.82 | MCL1 (0.39) | MCL1BCL2L1CSNK2A1ALDH1A1HPGD | |
| SCHEMBL130505 | 0.79 | CSNK2A1 (0.57) | MCL1BCL2L1CSNK2A1CA1CA2 | |
| SCHEMBL1520808 | 0.75 | MEN1 (0.61) | MCL1BCL2L1CSNK2A1CA1CA2 | |
| SCHEMBL3742173 | 0.75 | CSNK2A1 (0.67) | MCL1BCL2L1CSNK2A1CA1CA2 | |
| SCHEMBL9755080 | 0.74 | CSNK2A1 (0.50) | MCL1BCL2L1CSNK2A1CA1CA2 | |
| SCHEMBL2833452 | 0.72 | KDM4E (0.62) | MCL1CSNK2A1CA1CA2PTGS2 | |
| SCHEMBL1649282 | 0.72 | ALDH1A1 (0.62) | MCL1CSNK2A1CA1CA2PTGS2 | |
| SCHEMBL15965500 | 0.71 | KDM4C (0.51) | MCL1CSNK2A1CA1CA2PTGS2 | |
| SCHEMBL28810732 | 0.71 | MEN1 (0.60) | MCL1BCL2L1CSNK2A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| EP-1910275-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-02-13 | — | — | EP | claimed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | claimed |
| EP-2222291-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| WO-2009080828-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | MCL1 1756/4885BCL2L1 1218/4885CSNK2A1 871/4885 |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | MCL1 4848/4885BCL2L1 2028/4885CSNK2A1 562/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | MCL1 4516/4885BCL2L1 2230/4885CSNK2A1 2797/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MCL1 4837/4885BCL2L1 3906/4885CSNK2A1 655/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MCL1 4516/4885BCL2L1 2230/4885CSNK2A1 2797/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MCL1 4837/4885BCL2L1 3906/4885CSNK2A1 655/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | MCL1 1497/4885BCL2L1 925/4885CSNK2A1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.